Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: A systematic review and meta-analysis of randomized controlled trials

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1849-1856

  Ciliberto, Domenico ^a   Prati, Ubaldo ^a   Roveda, Laura ^a   Barbieri, Vito ^a   Staropoli, Nicoletta ^a   Abbruzzese, Alberto ^b   Caraglia, Michele ^b   Di Maio, Massimo ^c   Flotta, Domenico ^a   Tassone, Pierfrancesco ^a   Tagliaferri, Pierosandro ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Colorectal cancer; Liver metastases; Meta analysis; Resectable; Resected; Systematic review; Systemic chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LIVER METASTASIS; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT FAILURE;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84860721647     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1740     Document Type: Article

References (65)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
3. Benson AB III: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 13 (6 Suppl C): S5-S18, 2007.
4. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
5. Gennari L, Russo A and Rossetti C: Colorectal cancer: what has changed in diagnosis and treatment over the last 50 years? Tumori 93: 235-241, 2007. (Pubitemid 47080007)
6. Kosmider S and Lipton L: Adjuvant therapies for colorectal cancer. World J Gastroenterol 13: 3799-3805, 2007. (Pubitemid 47277226)
7. Wolpin BM, Meyerhardt JA, Mamon HJ and Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 57: 168-185, 2007. (Pubitemid 46798625)
8. Sauer R, Becker H, Hohenberger W, et al: German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
9. ESMO Guidelines Working Group, Van Cutsem EJ: Advanced colorectal cancer: ESMO clinical recommendations for diagnosis,treatment and follow-up. Ann Oncol 18 (Suppl 2): ii25-6, 2007.
10. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420-1425, 2004. (Pubitemid 39429665)
11. Wagner JS, Adson MA, Van Heerden JA, Adson MH and Ilstrup DM: The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199: 502-508, 1984. (Pubitemid 14105105)
12. McMillan DC and McArdle CS: Epidemiology of colorectal liver metastases. Surg Oncol 16: 3-5, 2007. (Pubitemid 46887664)
13. Al-Asfoor A and Fedorowicz Z: WITHDRAWN: Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev 17: CDUO6039, 2007.
14. Stein U and Schlag PM: Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 176: 61-80, 2007.
15. McLoughlin JM, Jensen EH and Malafa M: Resection of colorectal liver metastases: current perspectives. Cancer Control 13: 32-41, 2006. (Pubitemid 43327552)
16. Adson MA: Resection of liver metastases: When is it worthwhile? World J Surg 11: 511-520, 1987. (Pubitemid 17137106)
17. Scheele J, Stangl R, Altendorf-Hofman A, et al: Resection of colorectal liver metastases. World J Surg 19: 59-71, 1995.
18. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection-registry of hepatic metastases. Surgery 103: 278-288, 1988.
19. Stangl R, Altendorf-Hofman A, Charnley RM, et al: Factors influencing the natural history of colorectal liver metastases. Lancet 343: 1405-1410, 1994. (Pubitemid 24167517)
20. Jaeck D, Bachellier P, Guiguet M, et al: Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 84: 977-980, 1997. (Pubitemid 27310867)
21. Fong Y, Cohen AM, Fortner JG, et al: Liver resection for colorectal metastases. J Clin Oncol 15: 938-946, 1997. (Pubitemid 27106275)
22. Scheele J, Altendorf-Hofmann A, Grube T, et al: Resection of colorectal liver metastases: what prognostic factors determine patient selection? Chirurg 72: 547-560, 2001 (In German). (Pubitemid 33678653)
23. Pawlik TM, Schulick RD and Choti MA: Expanding criteria for resectability of colorectal liver metastases. Oncologist 13: 51-64, 2008. (Pubitemid 351206696)
24. Garden OJ, Rees M, Poston GJ, et al: Guidelines for resection of colorectal cancer liver metastases. Gut 55 (Suppl 3): iii1-iii8, 2006. (Pubitemid 44085662)
25. Poston GJ, Adam R, Alberts S, et al: OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23: 7125-7134, 2005.
26. Steele G Jr and Ravikumar TS: Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 210: 127-138, 1989.
27. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
28. Gallagher DJ and Kemeny N: Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78: 237-248, 2010.
29. Bozzetti F, Doci R, Bignami P, Morabito A and Gennari L: Patterns of failure following surgical resection of colorectal cancer liver metastases: rationale for a multimodal approach. Ann Surg 205: 264-270, 1987. (Pubitemid 17037049)
30. Topal B, Kaufman L, Aerts R and Penninckx F: Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 29: 248-253, 2003. (Pubitemid 36395560)
31. Delaunoit T, Alberts SR, Sargent DJ, et al: Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 16: 425-429, 2005. (Pubitemid 40458319)
32. Bismuth H, Adam R, Levi F, et al: Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224: 509-520, 1996.
33. Adam R, Huguet E, Azoulay D, et al: Hepatic resection after down-staging of unresectable hepatic colorectal metastases. Surg Oncol Clin N Am 12: 211-220, 2003. (Pubitemid 36204988)
34. Giacchetti S, Itzhaki M, Gruia G, et al: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10: 663-669, 1999. (Pubitemid 29342371)
35. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240: 644-657, 2004.
36. Pozzo C, Basso M, Quirino M, et al: Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with Irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. Br J Cancer 97: 1035-1039, 2007. (Pubitemid 47587006)
37. Alberts SR, Horvath WL, Sternfeld WC, et al: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23: 9243-9249, 2005.
38. Higgins JPT and Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from: www.mrc-bsu.cam.ac.uk/cochrane/handbook502.
39. Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101, 1994.
40. Deeks, JJ, Altman DG and Bradburn MJ: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Systematic Reviews in Health Care: Meta-Analysis in Context. Egger M, Smith GD and Altman DG (eds). 2nd edition. BMJ Publication Group, London, 2001.
41. Sterne JAC, Harris RJ, Harbord RM and Steichen TJ: User-written packages for meta-analysis in Stata, 2007. Available from: http://www.stata.com/support/ fags/stat/meta.html/
42. Bathe OF, Dowden S, Sutherland F, et al: Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer 4: 32, 2004.
43. Wein A, Riedel C, Brückl W, et al: Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 64: 131-138, 2003. (Pubitemid 36173378)
44. Lorenz M, Staib-Sebler E, Gog C, et al: Prospective pilot study of neoadjuvant chemotherapy with 5- fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir 128: 87-94, 2003. (Pubitemid 36342913)
45. Taïeb J, Artru P, Paye F, et al: Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 23: 502-509, 2005. (Pubitemid 46224226)
46. Boxberger F, Albrecht H, Konturek PC, et al: Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial. Med Sci Monit 16: CR49-CR55, 2010.
47. Bathe OF, Ernst S, Sutherland FR, et al: A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 9: 156, 2009.
48. Lubezky N, Geva R, Shmueli E, Nakache R, Klausner JM, Figer A and Ben-Haim M: Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? World J Surg 33: 1028-1034, 2009.
49. Ychou M, Hohenberger W, Thezenas S, et al: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20: 1964-1970, 2009.
50. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26: 4906-4911, 2008.
51. Uzzan B, Mariani P, Nicolas P, Perret, G Morere J and des Guetz G: Systemic or hepatic arterial chemotherapy is useful after curative resection of liver metastases from colorectal cancer. A meta-analysis of randomized controlled trials. J Clin Oncol 26 (Suppl): 4077, 2008.
52. Langer B, Bleiberg H, Labianca R, Shepherd L, et al: Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 21: 592, 2002.
53. Lopez-Ladron A, Salvador J, Bernabe R, et al: Observation versus postoperative chemotherapy after resection of liver metastases in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 22: 1497, 2003.
54. Portier G, Elias D, Bouche O, et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24: 4976-4982, 2006. (Pubitemid 46631399)
55. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
56. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25: 5218-5224, 2007. (Pubitemid 350232253)
57. Tang PA, Bentzen SM, Chen EX and Siu LL: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568, 2007. (Pubitemid 350035313)
58. Sargent DJ, Patiyil S, Yothers G, et al: ACCENT Group: End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25: 4569-4574, 2007. (Pubitemid 350035314)
59. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23: 8664-8670, 2005. (Pubitemid 46211509)
60. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, et al: Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 249: 420-425, 2009.
61. Folprecht G, Grothey A, Alberts S, et al: Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319, 2005. (Pubitemid 41158476)
62. Nordlinger B and Benoist S: Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 24: 4954-4955, 2006. (Pubitemid 46631395)
63. Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945, 2006. (Pubitemid 46630742)
64. Kinkel K, Lu Y, Both M, Warren RS and Thoeni RF: Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224: 748-756, 2002. (Pubitemid 34919808)
65. Nordlinger B, Van Cutsem E, Rougier P, et al: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 43: 2037-2045, 2007. (Pubitemid 47380368)